Business Description
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Business History
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.59
Total Equity: $6.74B
Shares: 284,000,000
Total Debt: $3.35B
Cash: $1.79B
EBITDA: $1.84B
Total Debt: $3.35B
Cash: $1.79B
Revenue: $6.95B
Revenue: $6.95B
Revenue: $6.95B
Total Equity: $6.74B
Tax Rate: 9.2%
Equity: $6.74B
Total Debt: $3.35B
Cash: $1.79B
Current Liabilities: $2.35B
Long-Term Debt: $3.05B
Total Debt: $3.35B
Total Equity: $6.74B
Shares: 284,000,000
Shares: 284,000,000
CapEx: -$407.00M
Shares: 284,000,000
Stock Price: $136.01
Net Income: $1.30B
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:06pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $6.3B | $6.8B | $6.8B | $6.5B | $6.9B |
| Cost of Revenue | $2.9B | $3.1B | $3.4B | $3.0B | $3.3B |
| Gross Profit | $3.4B | $3.7B | $3.5B | $3.5B | $3.6B |
| Operating Expenses | $2.1B | $2.1B | $2.1B | $2.0B | $2.2B |
| Operating Income | $1.3B | $1.6B | $1.4B | $1.5B | $1.5B |
| Net Income | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B |
| EBITDA | $1.8B | $1.9B | $1.7B | $1.9B | $1.8B |
| EPS | $3.98 | $4.19 | $4.22 | $4.44 | $4.59 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:06pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.5B | $1.1B | $1.6B | $1.3B | $1.8B |
| Total Current Assets | $3.8B | $3.8B | $4.2B | $4.0B | $4.6B |
| Total Assets | $10.7B | $10.5B | $10.8B | $11.8B | $12.7B |
| Current Liabilities | $1.7B | $1.9B | $1.6B | $1.9B | $2.3B |
| Long-Term Debt | $2.7B | $2.7B | $2.7B | $3.3B | $3.1B |
| Total Liabilities | $5.3B | $5.2B | $4.9B | $5.9B | $6.0B |
| Total Equity | $5.4B | $5.3B | $5.8B | $5.9B | $6.7B |
| Retained Earnings | $348.0M | $324.0M | $782.0M | $750.0M | $1.4B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:06pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.5B | $1.3B | $1.8B | $1.8B | $1.6B |
| Capital Expenditure | -$189.0M | -$291.0M | -$298.0M | -$378.0M | -$407.0M |
| Free Cash Flow | $1.3B | $1.0B | $1.5B | $1.4B | $1.2B |
| Acquisitions (net) | -$546.0M | -$52.0M | -$1.0M | -$862.0M | $4.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$788.0M | -$1.1B | -$575.0M | -$1.2B | -$425.0M |
| Net Change in Cash | $43.0M | -$434.0M | $537.0M | -$261.0M | $459.0M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 9:50pm (12h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$7.9B $7.8B – $8.0B
|
$8.4B $8.4B – $8.4B
|
$8.9B $8.8B – $8.9B
|
$9.4B $9.3B – $9.5B
|
| EBITDA |
$2.1B $2.1B – $2.2B
|
$2.3B $2.3B – $2.3B
|
$2.4B $2.4B – $2.4B
|
$2.5B $2.5B – $2.6B
|
| Net Income |
$1.9B $1.8B – $1.9B
|
$2.1B $1.9B – $2.2B
|
$2.3B $2.3B – $2.3B
|
$2.5B $2.5B – $2.5B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:06pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +8.4% | -0.2% | -4.7% | +6.7% |
| Gross Profit Growth | +9.2% | -6.9% | +2.0% | +3.1% |
| Operating Income Growth | +20.1% | -16.6% | +10.2% | -0.6% |
| Net Income Growth | +3.6% | -1.1% | +4.0% | +1.1% |
| EBITDA Growth | +8.1% | -10.6% | +10.0% | -2.1% |
Dividend History (Last 20)
Last updated: Jun 21, 2026 7:06pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-30 | $0.26 | 2026-05-20 | 2026-06-30 | 2026-07-22 |
| 2026-03-31 | $0.26 | 2026-02-11 | 2026-03-31 | 2026-04-22 |
| 2026-01-06 | $0.26 | 2025-11-19 | 2026-01-06 | 2026-01-28 |
| 2025-09-30 | $0.25 | 2025-09-17 | 2025-09-30 | 2025-10-22 |
| 2025-07-01 | $0.25 | 2025-05-21 | 2025-07-01 | 2025-07-23 |
| 2025-04-01 | $0.25 | 2025-02-19 | 2025-04-01 | 2025-04-23 |
| 2024-12-31 | $0.25 | 2024-11-20 | 2024-12-31 | 2025-01-22 |
| 2024-10-01 | $0.24 | 2024-09-18 | 2024-10-01 | 2024-10-23 |
| 2024-07-02 | $0.24 | 2024-05-22 | 2024-07-02 | 2024-07-24 |
| 2024-04-01 | $0.24 | 2024-02-21 | 2024-04-02 | 2024-04-24 |
| 2023-12-29 | $0.24 | 2023-11-15 | 2024-01-02 | 2024-01-24 |
| 2023-10-02 | $0.23 | 2023-09-20 | 2023-10-03 | 2023-10-25 |
| 2023-06-30 | $0.23 | 2023-05-17 | 2023-07-03 | 2023-07-26 |
| 2023-04-03 | $0.23 | 2023-02-22 | 2023-04-04 | 2023-04-26 |
| 2022-12-30 | $0.23 | 2022-11-16 | 2023-01-03 | 2023-01-25 |
| 2022-10-03 | $0.21 | 2022-09-21 | 2022-10-04 | 2022-10-26 |
| 2022-07-01 | $0.21 | 2022-05-18 | 2022-07-05 | 2022-07-27 |
| 2022-04-04 | $0.21 | 2022-02-15 | 2022-04-05 | 2022-04-27 |
| 2022-01-03 | $0.21 | 2021-11-17 | 2022-01-04 | 2022-01-26 |
| 2021-10-04 | $0.19 | 2021-09-22 | 2021-10-05 | 2021-10-27 |
Narrative Economics
market-narrative step).